Lifecycle evaluation of medical devices: supporting or jeopardizing patient outcomes? A comparative analysis of evaluation models.

IF 2.6 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES International Journal of Technology Assessment in Health Care Pub Date : 2024-01-05 DOI:10.1017/S026646232300274X
Kathleen R Harkin, Jan Sorensen, Steve Thomas
{"title":"Lifecycle evaluation of medical devices: supporting or jeopardizing patient outcomes? A comparative analysis of evaluation models.","authors":"Kathleen R Harkin, Jan Sorensen, Steve Thomas","doi":"10.1017/S026646232300274X","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Lack of evidence regarding safety and effectiveness at market entry is driving the need to consider adopting a lifecycle approach to evaluating medical devices, but it is unclear what lifecycle evaluation means. This research sought to explore the tacit meanings of \"lifecycle\" and \"lifecycle evaluation\" as embodied within evaluation models/frameworks used for medical devices.</p><p><strong>Methods: </strong>Drawing on qualitative evidence synthesis methods and using an inductive approach, novel methods were developed to identify, appraise, analyze, and synthesize lifecycle evaluation models used for medical devices. Data was extracted (including purpose; audience; characterization; outputs; timing; and type of model) from key texts for coding, categorization, and comparison, exploring embodied meaning across four broad perspectives.</p><p><strong>Results: </strong>Fifty-two models were included in the synthesis. They demonstrated significant heterogeneity of meaning, form, scope, timing, and purpose. The \"lifecycle\" may represent a single stage, a series of stages, a cycle of innovation, or a system. \"Lifecycle evaluation\" focuses on the overarching goal of the stakeholder group, and may use a single or repeated evaluation to inform decision-making regarding the adoption of health technologies (Healthcare), resource allocation (Policymaking), investment in new product development or marketing (Trade and Industry), or market regulation (Regulation). The adoption of a lifecycle approach by regulators has resulted in the deferral of evidence generation to the post-market phase.</p><p><strong>Conclusions: </strong>Using a \"lifecycle evaluation\" approach to inform reimbursement decision-making must not be allowed to further jeopardize evidence generation and patient safety by accepting inadequate evidence of safety and effectiveness for reimbursement decisions.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10859834/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Technology Assessment in Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S026646232300274X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Lack of evidence regarding safety and effectiveness at market entry is driving the need to consider adopting a lifecycle approach to evaluating medical devices, but it is unclear what lifecycle evaluation means. This research sought to explore the tacit meanings of "lifecycle" and "lifecycle evaluation" as embodied within evaluation models/frameworks used for medical devices.

Methods: Drawing on qualitative evidence synthesis methods and using an inductive approach, novel methods were developed to identify, appraise, analyze, and synthesize lifecycle evaluation models used for medical devices. Data was extracted (including purpose; audience; characterization; outputs; timing; and type of model) from key texts for coding, categorization, and comparison, exploring embodied meaning across four broad perspectives.

Results: Fifty-two models were included in the synthesis. They demonstrated significant heterogeneity of meaning, form, scope, timing, and purpose. The "lifecycle" may represent a single stage, a series of stages, a cycle of innovation, or a system. "Lifecycle evaluation" focuses on the overarching goal of the stakeholder group, and may use a single or repeated evaluation to inform decision-making regarding the adoption of health technologies (Healthcare), resource allocation (Policymaking), investment in new product development or marketing (Trade and Industry), or market regulation (Regulation). The adoption of a lifecycle approach by regulators has resulted in the deferral of evidence generation to the post-market phase.

Conclusions: Using a "lifecycle evaluation" approach to inform reimbursement decision-making must not be allowed to further jeopardize evidence generation and patient safety by accepting inadequate evidence of safety and effectiveness for reimbursement decisions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
医疗器械的生命周期评估:支持还是损害患者的治疗效果?评估模式比较分析。
目标:由于缺乏进入市场时安全性和有效性方面的证据,因此需要考虑采用生命周期方法来评估医疗器械,但生命周期评估的含义尚不明确。本研究试图探索 "生命周期 "和 "生命周期评价 "在医疗器械评价模型/框架中的隐含含义:方法:借鉴定性证据综合方法,采用归纳法,开发了新方法来识别、评估、分析和综合用于医疗器械的生命周期评价模型。从关键文本中提取数据(包括目的、受众、特征描述、产出、时间和模型类型)进行编码、分类和比较,从四个广泛的角度探索体现的意义:结果:52 个模型被纳入综合研究。结果:有 52 个模型被纳入综述,这些模型在意义、形式、范围、时间和目的方面表现出明显的异质性。生命周期 "可以代表单一阶段、一系列阶段、创新周期或系统。"生命周期评价 "侧重于利益相关者群体的总体目标,可使用单次或重复评价,为有关采用卫生技术(医疗保健)、资源分配(决策)、新产品开发投资或营销(贸易与工业)或市场监管(监管)的决策提供信息。监管机构采用生命周期方法的结果是将证据生成推迟到上市后阶段:结论:使用 "生命周期评估 "方法为报销决策提供信息,绝不能接受不充分的安全性和有效性证据作为报销决策的依据,从而进一步损害证据的生成和患者的安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Technology Assessment in Health Care
International Journal of Technology Assessment in Health Care 医学-公共卫生、环境卫生与职业卫生
CiteScore
4.40
自引率
15.60%
发文量
116
审稿时长
6-12 weeks
期刊介绍: International Journal of Technology Assessment in Health Care serves as a forum for the wide range of health policy makers and professionals interested in the economic, social, ethical, medical and public health implications of health technology. It covers the development, evaluation, diffusion and use of health technology, as well as its impact on the organization and management of health care systems and public health. In addition to general essays and research reports, regular columns on technology assessment reports and thematic sections are published.
期刊最新文献
Development of an MCDA Framework for Rare Disease Reimbursement Prioritization in Malaysia. Experiences of patient organizations' involvement in medicine appraisal and reimbursement processes in Finland - a qualitative study. PP78 Real-World Trends And Medical Costs Of Stroke After Transcatheter Aortic Valve Implantation In Korea: A Nationwide, Population-Based Study Can requests for real-world evidence by the French HTA body be planned? An exhaustive retrospective case-control study of medicinal products appraisals from 2016 to 2021. A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1